EDNRA and lymphangioleiomyomatosis: To investigate EDN pathway involvement in LAM, we tested the effect of ERA such as bosentan (EDNRA and EDNRB inhibitors) and BQ123 (EDNRA inhibitor), with or without rapamycin (mTOR inhibitor) on cell proliferation.